TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
HALO

Halozyme Therapeutics Inc

Healthcare · Biotechnology

115.20$ +2.5% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

Halozyme Therapeutics Inc (HALO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 2,577 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet HALO
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
1,893 1,733 1,842 1,969 2,118 2,063 2,197 2,054 2,221 2,525 2,673 2,577
879 746 874 988 1,127 1,085 1,262 1,123 1,329 825 1,003 933
274 118 165 188 154 116 176 62 420 134 310 163
483 336 463 529 666 596 748 548 702 143 319 231
217 234 196 215 286 308 305 316 346 441 458 456
129 128 169 159 131 142 165 182 186 176 155 137
75 – – – – – – – – – – –
417 417 417 417 417 417 417 417 417 580 582 582
491 473 455 437 420 402 384 366 349 981 952 922
1,643 1,649 1,664 1,680 1,665 1,700 1,714 1,721 1,717 2,477 2,453 2,434
115 112 132 133 109 139 150 134 837 177 363 344
32 32 32 31 – – – – 711 – 209 209
19 12 13 15 12 10 20 19 15 21 14 24
1,498 1,499 1,501 1,503 1,504 1,506 1,507 1,509 800 2,143 1,936 1,938
249 84 178 289 453 364 482 333 504 49 220 144
222 91 167 261 398 360 478 361 502 55 205 151
134 131 129 129 130 129 127 124 122 118 123 121

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?